TITLE

Lower IQ is Associated with Decreased Clinical Response to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

AUTHOR(S)
Mazzone, Luigi; Reale, Laura; Mannino, Valeria; Cocuzza, Mariadonatella; Vitiello, Benedetto
PUB. DATE
June 2011
SOURCE
CNS Drugs;2011, Vol. 25 Issue 6, p503
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: Atomoxetine is commonly used to treat attention-deficit hyper- activity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. Methods: The records of all the children and adolescents treated with atomoxetine at a university clinic in Catania, Italy, over a 3-year period were examined. A total of 55 clinically referred children and adolescents (aged 5-15 years, 53 males) with ADHD were treated with atomoxetine (10-110 mg/day; mean: 1.28mg/kg/day) for a period ranging from 2 to 168 weeks (mean: 57.3± SD 39.4, median: 56). The IQ was assessed as part of the diagnostic evaluation prior to starting treatment. During treatment, clinical outcome was rated on the Clinical Global Impression-Improvement (CGI-I) and CGI-Severity (CGI-S) scales. Results: The IQ ranged from 43 to 117 (mean: 80.6± SD 18.6, median: 84). The IQ and final CGI-I scores were negatively correlated (r=-0.68; p<0.01). Children and adolescents with an IQ <85 were less likely to be responders (defined as a final CGI-I score of 1 or 2) than children and adolescents with an IQ ≥ 85 (20.71% vs 76.9%; p<0.001). None of the patients discontinued atomoxetine due to adverse effects, while treatment was dis- continued in 20 subjects due to a lack of efficacy or ambivalence of parents about pharmacological treatment. Conclusions: Atomoxetine appears to be less effective in children and adolescents with an IQ <85 than in children and adolescents in the average range of cognitive functioning. This difference is not accounted for by differences in the severity of ADHD symptoms, co-morbidity or reduced tolerability to the medication. These findings suggest that, in order to be fully informative, clinical trials of medications for ADHD should also include children and adolescents functioning in the borderline and cognitive disability range.
ACCESSION #
64291262

 

Related Articles

  • Full syndrome and subthreshold attention-deficit/hyperactivity disorder in a Korean community sample: comorbidity and temperament findings. Soo-Churl Cho; Boong-Nyun Kim; Jae-Won Kim; Luis Augusto Rohde; Jun-Won Hwang; Dong-Seon Chungh; Min-Sup Shin; In Kyoon Lyoo; Bock-Ja Go; Sang-Eun Lee; Hyo-Won Kim // European Child & Adolescent Psychiatry;Jul2009, Vol. 18 Issue 7, p447 

    The main objective of this study was to investigate the comorbid disorders and temperamental profiles of full syndrome and subthreshold attention-deficit/hyperactivity disorder (ADHD). A sample of 2,493 students was randomly selected from six representative elementary schools in Seoul, Korea....

  • A diagnosis of ADHD? Don't overlook the probability of comorbidity! Adesman, Andrew // Contemporary Pediatrics;Dec2003, Vol. 20 Issue 12, p91 

    Discusses the probability of comorbidity in the diagnosis of attention deficit hyperactivity disorder (ADHD). Percentage of the prevalence of comorbidity in children with ADHD; Factors that influence the prevalence of specific disorders; Data on developmental disorders associated with ADHD;...

  • Diferencias en funciones ejecutivas en escolares normales, con trastorno por déficit de atención e hiperactividad, trastorno del cálculo y condición comórbida. GAITÁN CHIPATECUA, ALEXANDRA; REY-ANACONA, CESAR ARMANDO // Avances en PsicologÍa Latinoamericana;2013, Vol. 31 Issue 1, p71 

    The goal of this study was to compare the executive functions in children from 8 to 13 years old with Attention Deficit Hyperactivity Disorder (ADHD), Dyscalculia (TC), ADHD+TC, and normal controls. The diagnoses were confirmed through a semi-structured clinical interview, attentional-deficit...

  • Comorbidade entre o transtorno de déficit de atenção/ hiperatividade e o abuso e dependência de álcool e outras drogas: evidências por meio de modelos animais. Vendruscolo, Leandro F.; Takahashi, Reinaldo N. // Revista Brasileira de Psiquiatria;jun2011, Vol. 33 Issue 2, p203 

    Objective: To describe some recent theories regarding the comorbidity between attention deficit/hyperactivity disorder and substance use disorders and discuss the utility of using spontaneously hypertensive rats (an animal model of attention deficit/hyperactivity disorder) for the study of...

  • Differential family and peer environmental factors are related to severity and comorbidity in children with ADHD. Buschgens, C. J. M.; van Aken, M. A. G.; Swinkels, S. H. N.; Altink, M. E.; Fliers, E. A.; Rommelse, N. N. J.; Minderaa, R. B.; Sergeant, J. A.; Faraone, S. V.; Buitelaar, J. K. // Journal of Neural Transmission;Feb2008, Vol. 115 Issue 2, p177 

    Behavioral genetic studies imply that salient environmental influences operate within families, making siblings in a family different rather than similar. This study is the first one to examine differential sibling experiences (as measured with the Sibling Inventory of Differential Experience)...

  • New Options for ADHD. Schonwald, Alison D.; Rappaport, Leonard // Newsweek (Pacific Edition);9/22/2003 (Pacific Edition), Vol. 142 Issue 12, p53 

    Discusses the various options for treating attention deficit hyperactivity disorder (ADHD) in children. Use of drugs such as Benzedrine, Dexedrine, and Ritalin to treat patients; lack of flexibility in treatments; Abuse of drug stimulants; How the drug may take weeks to be affective;...

  • Sluggish Cognitive Tempo (Concentration Deficit Disorder?): Current Status, Future Directions, and a Plea to Change the Name. Barkley, Russell // Journal of Abnormal Child Psychology;Jan2014, Vol. 42 Issue 1, p117 

    Symptoms of sluggish cognitive tempo (SCT) have been recognized for nearly 30 years as comprising a semi-independent set(s) of symptoms from the inattentive (IN) and hyperactive-impulsive (HI) symptoms involved in attention-deficit/hyperactivity disorder (ADHD). It has only been within the past...

  • The Separation of ADHD Inattention and Hyperactivity-Impulsivity Symptoms: Pathways from Genetic Effects to Cognitive Impairments and Symptoms. Kuntsi, Jonna; Pinto, Rebecca; Price, Thomas; Meere, Jaap; Frazier-Wood, Alexis; Asherson, Philip // Journal of Abnormal Child Psychology;Jan2014, Vol. 42 Issue 1, p127 

    Both shared and unique genetic risk factors underlie the two symptom domains of attention deficit hyperactivity disorder (ADHD): inattention and hyperactivity-impulsivity. The developmental course and relationship to co-occurring disorders differs across the two symptom domains, highlighting the...

  • The Relationship Between Sluggish Cognitive Tempo and Impairment in Children With and Without ADHD. Watabe, Yuko; Owens, Julie; Evans, Steven; Brandt, Nicole // Journal of Abnormal Child Psychology;Jan2014, Vol. 42 Issue 1, p105 

    This study examined impairment in multiple domains of functioning in children with and without ADHD who present with high or low levels of sluggish cognitive tempo (SCT) while taking into account the total symptom ratings of ADHD. Participants were 584 children in kindergarten through eighth...

  • ADHD in the Classroom. Bose, Dev Kumar // Currents in Teaching & Learning;Fall2012-Spring2013, Vol. 5 Issue 1&2, p94 

    The article offers information on attention-deficit/hyperactivity disorder (ADHD) which has been described as persistent pattern of inattention and/or hyperactivity-impulsivity. Noted is that ADHD affects cognitive and executive functions such as activation, focus, and memory. Described are the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics